Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)

The treatment landscape for small-cell lung cancer (SCLC) has seen significant advances in the past few years. Previously, chemotherapy and radiotherapy were the predominant treatments, but treatment has evolved with the approvals of targeted immunotherapies (Genentech’s atezolizumab in 2019, AstraZeneca’s durvalumab in 2020, Amgen’s tarlatamab in 2024) for extensive-stage disease. Additionally, durvalumab’s label expansion to the limited-stage setting represented groundbreaking approval in this space. Despite these advances, significant unmet need remains for more therapeutic options that offer durable responses, especially in the later lines of treatment. Although the late-phase pipeline for SCLC is relatively modest, it will help drive market growth as Daiichi’s antibody-drug conjugate (ADC) ifinatamab deruxtecan and Gilead’s sacituzumab govitecan are forecast to approve for later-line SCLC. Nevertheless, there is still considerable commercial potential for targeted therapies for SCLC.

Questions answered

• How will the recent approval of tarlatamab impact the treatment of second- and third-line extensive-stage SCLC?
• How will the approval of durvalumab as consolidation therapy for limited-stage patients impact the SCLC treatment paradigm?
• What are the key emerging therapies poised to enter the SCLC market, and what level of uptake and sales can be expected over the 2023-2033 forecast period?
• What are the key drivers and constraints shaping the SCLC market, and how will treatment dynamics evolve across major markets?

Geography: United States, EU5, Japan.

Primary research: 19 country-specific interviews with thought-leading medical oncologists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Incidence of SCLC by country, segmented by limited-stage and extensive-stage disease.

Forecast: 10-year, annualized, drug-level sales and patient share of key SCLC therapies through 2033, segmented by brands / generics and epidemiological subpopulations.

Drug treatments: Coverage of key current and emerging therapies.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.